Gain Therapeutics (GANX) Tax Provisions (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Tax Provisions of $183066.0 for Q1 2026, up 82.14% year-over-year from $100509.0 in Q1 2025, and up 103.78% quarter-over-quarter from -$4.8 million in Q4 2025.
Gain Therapeutics (GANX) Tax Provisions (2020 - 2026) Analysis & Trends
Gain Therapeutics' Tax Provisions history runs 7 years deep, the most recent figure standing at $183066.0 for Q1 2026.
- In Q1 2026, Tax Provisions rose 82.14% year-over-year to $183066.0; the TTM figure through Mar 2026 stood at -$4.0 million (down 743.0% YoY), while the FY2025 annual figure was -$4.1 million, down 855.01% from the prior year.
- Tax Provisions for Q1 2026 stood at $183066.0, up from -$4.8 million in the prior quarter.
- The five-year high for Tax Provisions was $549000.0 in Q3 2025, with the low at -$4.8 million in Q4 2025.
- The 5-year median for Tax Provisions is $19874.0 (2024), against an average of -$185945.1.
- Peak annual rise in Tax Provisions reached 11579.49% in 2025, while the deepest fall reached 1059.56% in 2025.
- Gain Therapeutics' Tax Provisions stood at $78105.0 in 2022, then slumped by 81.43% to $14502.0 in 2023, then jumped by 3381.0% to $504815.0 in 2024, then tumbled by 1059.56% to -$4.8 million in 2025, then jumped by 103.78% to $183066.0 in 2026.
- Business Quant data shows GANX's Tax Provisions at $183066.0 in Q1 2026, -$4.8 million in Q4 2025, and $549000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 104,070.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104,070.00 |
| Mar 31, 2026 | 183,066.00 |
| Dec 31, 2025 | -4.84 Mn |
| Sep 30, 2025 | 549,000.00 |
| Jun 30, 2025 | 141,205.00 |
| Mar 31, 2025 | 100,509.00 |
| Dec 31, 2024 | 504,815.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 1,209.00 |
| Mar 31, 2024 | 19,874.00 |
| Dec 31, 2023 | 14,502.00 |
| Sep 30, 2023 | 21,456.00 |
| Jun 30, 2023 | 26,589.00 |
| Mar 31, 2023 | 16,728.00 |
| Dec 31, 2022 | 78,105.00 |
| Sep 30, 2022 | 4,048.00 |
| Jun 30, 2022 | 9,146.00 |
| Mar 31, 2022 | 1,677.00 |
| Dec 31, 2021 | -8,244.00 |
| Sep 30, 2021 | 5,114.00 |